• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Focus Surgery posts 1994 results

Article

Focus Surgery's net loss widened last year as the company geared up its sales and marketing effortfor Sonablate 200, which uses high-intensity focused ultrasoundto treat benign prostatic hyperplasia (SCAN 9/28/94). The Fremont,CA, firm reported total

Focus Surgery's net loss widened last year as the company geared up its sales and marketing effortfor Sonablate 200, which uses high-intensity focused ultrasoundto treat benign prostatic hyperplasia (SCAN 9/28/94). The Fremont,CA, firm reported total revenues for 1994 (end-December) of $1.6million, compared to total revenues of $1.9 million the year before.Focus Surgery's net loss grew to $7.7 million, compared to $6.6million in 1993. Sonablate 200 was granted German regulatory approvallast year and Focus has made six commercial sales worldwide. Focusis working on a premarket approval (PMA) application to the Foodand Drug Administration to sell the system in the U.S.

Related Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.